Commercial-scale manufacture of lentivirus for ex vivo and in vivo therapies

As the field of lentivirus (LV) progresses toward large-scale manufacturing to generate sufficient functional LVs for treating patients, scalability and consistency are important aspects to consider.  This poster presents case study data to show how TFDF enables a scalable perfusion process that can provide sufficient LV doses for large patient populations.

Please enter your email to access content Read now